Vimarsana
Biggest News Aggregation in the World

Page 21 - Mobile Opera News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mobile Opera. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mobile Opera Today - Breaking & Trending Today

Sickle cell disease: Expanded surveillance, new treatments and the power of music therapy - Vimarsana News

Sickle cell disease: Expanded surveillance, new treatments and the power of music therapy

World Sickle Cell Day is observed each year on June 19.The observation is intended to raise awareness of sickle cell disease, as well as the challenges patients encounter.

Source: healio.com
HHS, USDA seek nominations for Dietary Guidelines Advisory Committee - Vimarsana News

HHS, USDA seek nominations for Dietary Guidelines Advisory Committee

HHS and the United States Department of Agriculture are accepting nominations for an advisory committee that will review evidence and develop recommendations for the 2025-2030 Dietary Guidelines for Americans.

Source: healio.com
Overuse of asthma rescue inhalers common, varies among practices - Vimarsana News

Overuse of asthma rescue inhalers common, varies among practices

Rates of overprescribing of short-acting beta agonist asthma inhalers remain high and vary significantly among practices, according to new data published in the British Journal of General Practice.Researchers conducted a cross-sectional study to quantify the prevalence of SABA overprescribing and identify predictors that lead to overprescribing. The researchers evaluated 30,694 primary care

Source: healio.com
NEI researchers discover potential new type of macular dystrophy - Vimarsana News

NEI researchers discover potential new type of macular dystrophy

Researchers from the National Eye Institute found TIMP3 variants cause atypical presentations of Sorsby fundus dystrophy, potentially indicating a different type of macular dystrophy not previously classified.

Source: healio.com
Quizartinib regimen extends survival vs. chemotherapy in acute myeloid leukemia subgroup - Vimarsana News

Quizartinib regimen extends survival vs. chemotherapy in acute myeloid leukemia subgroup

Adding quizartinib to standard chemotherapy and up to 3 years of continuation therapy extended OS among a subset of older adults with newly diagnosed acute myeloid leukemia, according to results of the phase 3 QuANTUM-First trial.The findings, presented during the European Hematology Association Hybrid 2022 Congress, additionally showed quizartinib (Daiichi Sankyo) had a favorable safety profile,

Source: healio.com